Published by Josh White on 8th February 2022
(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma said on Tuesday that it has received positive scientific advice from the European Medicines Agency (EMA), following its review of its proposed phase 3 clinical programme design.
URL: http://www.digitallook.com/dl/news/story/32448859/...